Progesterone block prevents breast cancer

Blocking progesterone may prevent or halt the development of breast and ovarian cancers in women with mutations of the BRCA1 gene, findings of a study suggest.

The study of mice lacking BRCA1 and the gene p53 showed that mammary tumours developed in an average of eight months. However, mice given the progesterone antagonist mifepristone were free of tumours at 12 months.  

In mice lacking BRCA1 and p53, there were more epithelial cells with progesterone receptors than in mice lacking the gene p53 only.  

The role of progesterone in BRCA1-mutation cancers could explain why they occur only in breast and ovarian tissue.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women, children and under-18s will not be recommended for routine COVID-19...

GP training: How an audit e-portfolio log entry is assessed

GP training: How an audit e-portfolio log entry is assessed

The second of two articles on audit during GP training looks at how the quality improvement...

GP training: Writing up an audit for your e-portfolio

GP training: Writing up an audit for your e-portfolio

In the first of two articles on how to write up an audit, a typical e-portfolio entry...

UK ups order of 95% effective COVID-19 vaccine by 2m doses

UK ups order of 95% effective COVID-19 vaccine by 2m doses

The UK has increased its order of the 95% effective Moderna COVID-19 vaccine to 7m...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Which COVID-19 vaccines are lined up for roll-out on the NHS?

Which COVID-19 vaccines are lined up for roll-out on the NHS?

As GPs and their teams prepare for delivering a COVID-19 vaccination programme that...